Abstract
Multiple sclerosis is fundamentally an inflammatory demyelinating illness affecting the brain and spinal cord. The typical clinical feature of relapsing and remitting episodes of neurological disability reflects this pathological hallmark. However, some of the earliest neuropathological descriptions of MS made reference to atrophy of the brain and spinal cord as well as microscopic axonal injury [1, 2] (see Kornek and Lassmann, 1999 for a comprehensive account on the historical reporting of axonal pathology in MS [3]). Likewise, it has long been recognised that most patients with relapsing-remitting MS will ultimately experience progressive accumulation of disability (secondary progression), while in others the accrual of disability is progressive from onset (primary progression). Advances in immunomodulatory therapy have revolutionised the care of patients with relapsing-remitting MS. Meanwhile, until recently, progressive forms of the illness remain stubbornly resistant to emerging therapies in a manner more in keeping with a neurodegenerative disease, although in the last few years a number of agents showed positive results in SPMS and PPMS trials. In recent years, a new light has been thrown on the neuropathology of MS, with focus often shifting towards neuro-axonal and grey matter pathology as possible correlates of progressive, irreversible disability. In this chapter, we hope to describe the hallmark white matter inflammatory demyelination of MS, to report on the relatively recent studies of neuro-axonal and grey matter pathology as seen in the progressive forms, and to reflect on the possible pathological correlates of progressive disability.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Carswell R. Pathological anatomy: illustrations of the elementary forms of disease. London: Longman; 1838.
Charcot JM. Histologie de la sclérose en plaques. Gaz Hôpitaux. 1868;41:554–5.
Kornek B, Lassmann H. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol. 1999;9:651–6.
Cox G. Theory and practice of histological techniques. New York: Churchill-Livingstone; 1977. p. 249–73.
Pittock SJ, et al. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry. 2005;76:1693–7.
Kolasinski J, et al. A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain. 2012;135:2938–51.
Kuhlmann T, et al. An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2016;133:13–24.
Frischer JM, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710–21.
Prineas JW, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol. 2001;50:646–57.
Ozawa K, et al. Patterns of oligodendroglia pathology in multiple-sclerosis. Brain. 1994;117:1311–22.
Frischer JM, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175–89.
Revesz T, Kidd D, Thompson AJ, Barnard RO, Mcdonald WI. A comparison of the pathology of primary and secondary progressive multiple-sclerosis. Brain. 1994;117:759–65.
Barnett MH, Parratt JDE, Cho E-S, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol. 2009;65:32–46.
Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17.
Breij ECW, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol. 2008;63:16–25.
Prineas JW, Connell F. Remyelination in multiple-sclerosis. Ann Neurol. 1979;5:22–31.
Barkhof F, et al. Remyelinated lesions in multiple sclerosis—magnetic resonance image appearance. Arch Neurol. 2003;60:1073–81.
Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain. 2002;125:338–49.
Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain. 2000;123:105–15.
Kwon EE, Prineas JW. Blood-brain-barrier abnormalities in longstanding multiple-sclerosis lesions-an immunohistochemical study. J Neuropathol Exp Neurol. 1994;53:625–36.
Leech S, Kirk J, Plumb J, McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol. 2007;33:86–98.
Plumb J, McQuaid S, Mirakhur M, Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol. 2002;12:154–69.
Claudio L, Raine CS, Brosnan CF. Evidence of persistent blood-brain-barrier abnormalities in chronic-progressive multiple-sclerosis. Acta Neuropathol. 1995;90:228–38.
Adams RA, et al. The fibrin-derived gamma(377–395) peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med. 2007;204:571–82.
Hochmeister S, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol. 2006;65:855–65.
Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120:393–9.
Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002;125:2202–12.
Kornek B, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis—a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 2000;157:267–76.
Trapp BD, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278–85.
Tallantyre EC, et al. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. Brain. 2009;132:1190–9.
Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893–901.
Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain. 2000;123:308–17.
Kutzelnigg A, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128:2705–12.
Seewann A, et al. Diffusely abnormal white matter in chronic multiple sclerosis imaging and histopathologic analysis. Arch Neurol. 2009;66:601–9.
Dawson JW. The histology of disseminated sclerosis. Trans R Soc Edinburgh. 1916;50:517–740.
Dinkler M. Zur Kasuistik der multiplen Herdsklerose des Gehirns und Ruckenmarks. Dtsch Z Nervenheilkd. 1904;26:233–47.
Sander M. Hirnrindenbefunde bei multiper Sklerose. Monatsschr Psychiatr Neurol. 1898;IV:427–36.
Schob F. Ein Betrag zur patologischen Anatomie der multiplen Sklerose. Monatsschr Psychiatr Neurol. 1907;22:62–87.
Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962;25:315–20.
Lumsden CE. In: Vinken PJ, Bruyn GW, editors. Handbook of clinical neurology. Amsterdam: North-Holland; 1970. p. 217–309.
Itoyama Y, et al. Immuno-cytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic-protein in multiple-sclerosis lesions. Ann Neurol. 1980;7:167–77.
Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol. 2003;62:723–32.
Vercellino M, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol. 2005;64:1101–7.
Kutzelnigg A, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol. 2007;17:38–44.
Gilmore CP, et al. Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. J Neurol Neurosurg Psychiatry. 2009;80:182–7.
Moll NM, et al. Cortical demyelination in PML and MS—similarities and differences. Neurology. 2008;70:336–43.
Papadopoulos D, et al. Substantial archaeocortical atrophy and neuronal loss in multiple sclerosis. Brain Pathol. 2009;19:238–53.
Haider L, et al. Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry. 2014;85:1386–95.
Gilmore CP, et al. Spinal cord gray matter demyelination in multiple sclerosis—a novel pattern of residual plaque morphology. Brain Pathol. 2006;16:202–8.
Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003;9:323–31.
Bo L, Geurts JJG, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol. 2007;64:76–80.
Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001;50:389–400.
Geurts JJG, et al. Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. Am J Neuroradiol. 2005;26:572–7.
Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 2006;67:960–7.
Magliozzi R, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–104.
Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164–74.
Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006;6:205–17.
Magliozzi R, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477–93.
Howell OW, et al. Extensive grey matter pathology in the cerebellum in multiple sclerosis is linked to inflammation in the subarachnoid space. Neuropathol Appl Neurobiol. 2015;41:798–813.
Kidd D, et al. Cortical lesions in multiple sclerosis. Brain. 1999;122:17–26.
Lucchinetti CF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188–97.
Trapp BD, Nave K-A. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–69.
Gilmore CP, et al. Spinal cord neuronal pathology in multiple sclerosis. Brain Pathol. 2009;19:642–9.
Klaver R, et al. Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. J Neuropathol Exp Neurol. 2015;74:453–8.
Juergens T, et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain. 2016;139:39–46.
Bruck W. The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage. J Neurol. 2005;252:V3–9.
Pesini P, et al. An immunohistochemical marker for Wallerian degeneration of fibers in the central and peripheral nervous system. Brain Res. 1999;828:41–59.
Al-Abdulla NA, Portera-Cailliau C, Martin LJ. Occipital cortex ablation in adult rat causes retrograde neuronal death in the lateral geniculate nucleus that resembles apoptosis. Neuroscience. 1998;86:191–209.
Bergers E, et al. Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology. 2002;59:1766–71.
Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol. 2000;47:391–5.
Ganter P, Prince C, Esiri MM. Spinal cord axonal loss in multiple sclerosis: a post-mortem study. Neuropathol Appl Neurobiol. 1999;25:459–67.
DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain. 2004;127:1009–18.
Dutta R, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol. 2006;59:478–89.
Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis—correlation with demyelination and inflammation. Brain. 2000;123:1174–83.
Mews I, Bergmann M, Bunkowski S, Gullotta F, Bruck W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler. 1998;4:55–62.
Barnes D, Munro PMG, Youl BD, Prineas JW, Mcdonald WI. The longstanding MS lesion—a quantitative MRI and electron-microscopic study. Brain. 1991;114:1271–80.
Singh S, et al. Relationship of acute axonal damage, Wallerian degeneration, and clinical disability in multiple sclerosis. J Neuroinflammation. 2017;14(1):57.
Androdias G, et al. Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords. Ann Neurol. 2010;68:465–76.
Dziedzic T, et al. Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol. 2010;20:976–85.
Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 1997;120:2149–57.
Sun D, Newman TA, Perry VH, Weller RO. Cytokine-induced enhancement of autoimmune inflammation in the brain and spinal cord: implications for multiple sclerosis. Neuropathol Appl Neurobiol. 2004;30:374–84.
Werner P, Pitt D, Raine CS. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol. 2001;50:169–80.
Lappe-Siefke C, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet. 2003;33:366–74.
Chari DM, Crang AJ, Blakemore WF. Decline in rate of colonization of oligodendrocyte progenitor cell (OPC)-depleted tissue by adult OPCs with age. J Neuropathol Exp Neurol. 2003;62:908–16.
Singh S, et al. Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol. 2013;125:595–608.
De Groot CJA, et al. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions—increased yield of active demyelinating and (p)reactive lesions. Brain. 2001;124:1635–45.
Correale J. The role of microglial activation in disease progression. Mult Scler J. 2014;20:1288–95.
Fischer MT, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain. 2012;135:886–99.
Ponath G, et al. Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology. Brain. 2017;140:399–413.
Brosnan CF, Raine CS. The astrocyte in multiple sclerosis revisited. Glia. 2013;61:453–65.
Correale J, Farez MF. The role of astrocytes in multiple sclerosis progression. Front Neurol. 2015;6:180.
Rossi S, et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler J. 2014;20:304–12.
Bartos A, et al. Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. J Neurol. 2007;254:20–5.
Rawes JA, Calabrese VP, Khan OA, DeVries GH. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult Scler. 1997;3:363–9.
Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64:402–4.
Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology. 2002;58:1372–81.
Hirano A, Llena JF. Morphology of central nervous system axons. In: Waxman SG, Kocsis JD, Stys PK, editors. The axon: structure, function and pathophysiology. New York: Oxford University Press; 1995. p. 49–67.
Campbell GR, Worrall JT, Mahad DJ. The central role of mitochondria in axonal degeneration in multiple sclerosis. Mult Scler J. 2014;20:1806–13.
Campbell GR, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol. 2011;69:481–92.
Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol. 2014;10:225–38.
Waxman SG. Acquired channelopathies in nerve injury and MS. Neurology. 2001;56:1621–7.
Smith KJ. Newly lesioned tissue in multiple sclerosis-a role for oxidative damage? Brain. 2011;134:1877–81.
Mahad DJ, et al. Mitochondrial changes within axons in multiple sclerosis. Brain. 2009;132:1161–74.
Meuth SG, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol. 2008;194:62–9.
Gnanapavan S, et al. Progression in multiple sclerosis is associated with low endogenous NCAM. J Neurochem. 2013;125:766–73.
Lovato L, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134:534–41.
Louapre C, Lubetzki C. Neurodegeneration in multiple sclerosis is a process separate from inflammation: yes. Mult Scler J. 2015;21:1626–8.
Kassmann CM, et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet. 2007;39:969–76.
Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study—9: Observations on the progressive phase of the disease. Brain. 2006;129:584–94.
Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–8.
Cottrell DA, et al. The natural history of multiple sclerosis: a geographically based study—5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122:625–39.
Runmarker B, Andersen O. Prognostic factors in a multiple-sclerosis incidence cohort with 25 years of follow-up. Brain. 1993;116:117–34.
Weinshenker BGEA. The natural-history of multiple-sclerosis—a geographically based study. Brain. 1989;112:133–46.
Bramow S, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010;133:2983–98.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Evangelou, N., Paine, S.M.L., Tallantyre, E.C. (2018). The Neuropathology of Progressive Multiple Sclerosis. In: Wilkins, A. (eds) Progressive Multiple Sclerosis. Springer, Cham. https://doi.org/10.1007/978-3-319-65921-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-65921-3_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-65920-6
Online ISBN: 978-3-319-65921-3
eBook Packages: MedicineMedicine (R0)